Mark Vincent
Director/Board Member en APTOSE BIOSCIENCES INC. .
Fortuna: 719 $ al 31/03/2024
Perfil
Mark D.
Vincent is the founder of Sarissa, Inc. (founded in 2000) where he holds the title of Chief Executive Officer & Director since 2011.
He is currently working as an Independent Director at Aptose Biosciences, Inc. since 2007 and as an Associate Professor at the University of Western Ontario since 2008.
Dr. Vincent has previously worked as a Director at DRI Capital, Inc. and as a Director-Investigational Oncology at YM BioSciences, Inc. He obtained his doctorate degree from the University of Cape Town in 1976.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
APTOSE BIOSCIENCES INC.
0.00% | 05/02/2024 | 433 ( 0.00% ) | 719 $ | 31/03/2024 |
Cargos activos de Mark Vincent
| Empresas | Cargo | Inicio |
|---|---|---|
| APTOSE BIOSCIENCES INC. | Director/Board Member | 19/09/2007 |
| Sarissa, Inc. | Founder | 01/01/2000 |
| University of Western Ontario | Corporate Officer/Principal | 01/01/2008 |
Antiguos cargos conocidos de Mark Vincent.
| Empresas | Cargo | Fin |
|---|---|---|
DRI Capital, Inc.
 DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Director/Board Member | - |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Formación de Mark Vincent.
| University of Cape Town | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| APTOSE BIOSCIENCES INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Finance |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
| Sarissa, Inc. |
- Bolsa de valores
- Insiders
- Mark Vincent
